News

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new

Stéphane Cohen joins Quantum Genomics as Director of Global Operations

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new

The Board of Directors of BOIRON, at its meeting on March 9, 2022 chaired by Thierry Boiron, made up the statutory and consolidated financial statements of the financial year ended on December 31

(Unaudited data)

QUARTERLY ACTIVITY IN 2021 (VARIATION AT CURRENT EXCHANGE RATES)

Press release

Paris, December 6, 2021

Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.

• Quantum Genomics will receive up to $20 M

Press release

Paris, November 25, 2021

Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.

• Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30%

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S. Patent

Press release

Paris, November 23, 2021

Dr. Catherine Llorens-Cortes receives the 2021 Emilia Valori Prize from the French Academy of Sciences

Quantum Genomics (Euronext Growth : ALQGC, OTCQX 

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that

Regulatory News:

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE:

IMV Inc. (NASDAQ: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 9 abstracts that will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held

Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the third quarter ending September 30, 2021 and

IMV Inc. (“IMV” or “the Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing immune-educating cancer therapies, based on its novel DPX platform, that target solid and blood

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare

Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for